Compare JQC & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JQC | DAWN |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.9M | 624.8M |
| IPO Year | N/A | 2021 |
| Metric | JQC | DAWN |
|---|---|---|
| Price | $5.01 | $8.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $26.56 |
| AVG Volume (30 Days) | 714.6K | ★ 2.6M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $133,672,000.00 |
| Revenue This Year | N/A | $15.51 |
| Revenue Next Year | N/A | $49.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.11 |
| 52 Week Low | $4.82 | $5.64 |
| 52 Week High | $5.65 | $13.53 |
| Indicator | JQC | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 47.22 |
| Support Level | $5.00 | $7.90 |
| Resistance Level | $5.08 | $8.67 |
| Average True Range (ATR) | 0.04 | 0.50 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 25.00 | 20.38 |
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.